Peptide Research Collection Library
Explore the compound
Quick Facts
Mechanism of Action
Cagrilintide is a long-acting amylin analog developed to support satiety and body-weight research. Its mechanism is associated with amylin-receptor signaling, delayed gastric emptying, and appetite-regulation pathways.
Mechanism of Action: is associated with amylin-receptor signaling, delayed gastric emptying, and appetite-regulation pathways.
- Supports appetite control and satiety signaling through amylin-pathway research [1].
- Associated with body-weight reduction signals in obesity studies, especially when paired with GLP-1 therapy [1].
- Investigated for metabolic-health endpoints including weight, waist size, and glucose-related measures [2].
- Complements incretin-style protocols in obesity research programs [1][2].
Research Applications & Context
Community-reported protocol schedules.
Research Dosage Information
Reported research quantities and their source context. These are not recommendations, and source status varies.
Scroll the table horizontally to read every column. Select a row to inspect it in the calculator.
Initiation: 0.25 mg Once weekly. Weeks 1-4. Step 2: 0.5 mg Once weekly. Weeks 5-8. Step 3: 1.0 mg Once weekly. Weeks 9-12. Step 4: 1.7 mg Once weekly. Weeks 13-16. Maintenance: 2.4 mg Once weekly. Weeks 17+.
| Phase | Reported Amount | Frequency | Draw Units | Cycle | Notes | Calculator |
|---|---|---|---|---|---|---|
| Initiation | 0.25 mg | Once weekly | Select a vial | Weeks 1-4 | Community-reported protocol. | |
| Step 2 | 0.5 mg | Once weekly | Select a vial | Weeks 5-8 | Community-reported protocol. | |
| Step 3 | 1.0 mg | Once weekly | Select a vial | Weeks 9-12 | Community-reported protocol. | |
| Step 4 | 1.7 mg | Once weekly | Select a vial | Weeks 13-16 | Community-reported protocol. | |
| Maintenance | 2.4 mg | Once weekly | Select a vial | Weeks 17+ | Community-reported protocol. |
Dosing Protocol & Schedule
Community-reported research schedules, not clinically validated protocols. Select a reported scenario and duration to calculate mathematical quantities.
| Period | Research Dose | Frequency | Total Injections | Total amount | Volume per entry | U-100 equivalent |
|---|
Strength changes affect volume and supplies, not the underlying community-reported quantities. Figures exceeding the selected syringe capacity are flagged; they are not instructions for splitting administrations.
Plan a Regimen Schedule
Save the selected research protocol to your private calendar. Scheduled entries never create Dose Logs.
Reconstitution Calculator
Select the vial strength you are examining. The reference chart displays examples, not recommended preparation volumes or validated protocols.
Reconstitution Reference Chart
Hypothetical volume comparisons for the selected vial. No particular volume is endorsed, and vial capacity, solubility, excipients and product-specific instructions are not established by this table.
| Example volume | Calculated concentration | Calculator |
|---|---|---|
| 1 mL | — | |
| 2 mL | — | |
| 3 mL | — | |
| 4 mL | — | |
| 5 mL | — |
Choose a compatible dry vial to see reference concentrations.
Research-only mathematical comparisons; not instructions to compound, prepare, or administer peptides. Community-reported protocols are not clinically validated by inclusion here.
Supplies Needed — Estimate
Select a vial strength and an example reconstitution volume below. Counts use only the checked, computable rows above; they are not product-specific sterility, compatibility, or stability guidance.
Select a compatible vial and volume below to view quantities.
Educational and entertainment purposes only. Research use only; not for human or animal administration. Pad counts assume two per Total entry; syringe counts include additional containers where a single entry exceeds the selected syringe capacity. Vial totals assume full theoretical recovery and do not account for dead volume, spoilage, asepsis, expiration, potency, route, or beyond-use dating. These figures are not a recommended supplies list for an actual procedure.
Published References (1 identified)
A recorded identifier identifies a publication; it does not establish that its claims have been independently verified.
- Once-weekly cagrilintide for weight management: a randomised phase 2 trial (2021) View source ↗ The Lancet — phase 2 trial · Publisher or publication identifier recorded; claim verification separate
Research indexes & other source links
Searches, registries and unverified source records are discovery resources, not verified published studies.
- PubMed.gov biomedical literature: Cagrilintide View source ↗ PubMed index/search · Source link recorded; claim verification separate
- ClinicalTrials.gov study registry: Cagrilintide View source ↗ ClinicalTrials.gov registry/search · Source link recorded; claim verification separate
- NIH/NCBI all-databases search: Cagrilintide View source ↗ NCBI database/search · Source link recorded; claim verification separate
- PubChem / NIH compound record search: Cagrilintide View source ↗ PubChem database/search · Source link recorded; claim verification separate
